CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Pfizer Inc. v. Apotex Inc.

1:13-cv-02022

Overview

Case Number 1:13-cv-02022
Filing Date 2013-12-11
Status Terminated
Termination Date 2015-06-29
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Defendant

Parties

Defendant

Apotex Inc. Operating Company

Represented By

10 Attorneys Listed

William A. Rakoczy

Email: wrakoczy@rmmslegal.com

Paul J. Molino

Email: paul@rmmslegal.com

Megan C. Haney

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Kevin P. Burke

Email: kburke@rmmslegal.com

Erin M. Forbes

UNDELIVERABLE EMAIL 2/5/2019

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

David A. Bilson

Phillips, Goldman, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, Goldman, McLaughlin & Hall, P.A., 1200 North Broom Street

Anuj K. Wadhwa

Email: awadhwa@rmmslegal.com

Richard L. Horwitz

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Plaintiff

UCB Pharma GmbH NPE (Individual / Inventor)

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Pfizer Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 9 proceedings
πŸ›οΈ
USPTO PTAB Trials 8 proceedings
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): πŸ‡©πŸ‡ͺ Germany πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (17 found):
PTAB: 8 U.S. Courts: 9
USPTO PTAB Trial 2016-08-22
IPR2016-01665

Amerigen Pharmaceuticals Limited et al. v. UCB Pharma GmbH

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-08-22
IPR2016-01596

Alembic Pharmaceuticals Limited v. UCB Pharma GmbH

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-08-18
IPR2016-01636

Torrent Pharmaceuticals Limited et al. v. UCB Pharma GmbH

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00514

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (7855230)
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00517

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (7985772)
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00516

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (8338478)
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00510

Mylan Pharmaceuticals Inc et al. v. UCB Pharma GmbH

Asserted Patent
Status: Final Written Decision
USPTO PTAB Trial 2016-01-28
IPR2016-00512

Mylan Pharmaceuticals Inc. et al. v. UCB Pharma GmbH

U.S. Continuation Sibling (7384980)
Status: Final Written Decision
U.S. District Court 2017-02-02
1:17-cv-00112

Pfizer Inc. v. Torrent Pharmaceuticals Limited

Asserted Patent
Status: DED
U.S. District Court 2015-11-18
1:15-cv-01067

Pfizer Inc. v. Dr. Reddy's Laboratories Ltd.

Asserted Patent
Status: DED
U.S. District Court 2013-12-11
1:13-cv-02021

Pfizer Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-08-02
1:13-cv-01387

Pfizer Inc. v. Wockhardt Bio AG

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01156

Pfizer Inc. v. Amerigen Pharmaceuticals Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01155

Pfizer Inc. v. Accord Healthcare Inc.USA

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01158

Pfizer Inc. v. Impax Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01153

Pfizer Inc. v. Lupin Ltd

Asserted Patent
Status: DED
U.S. District Court 2013-06-28
1:13-cv-01154

Pfizer Inc. v. Zydus Pharmaceuticals (USA)Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

8 Patents

There are 8 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6858650
Stable salts of novel derivatives of 3,3-diphenylpropylamines
Filed: 2000-11-15
Issued: 2005-02-22
Expired (Term Ended) +1149d PTA
Expires: 2024-01-08
US7807715
Pharmaceutical compositions comprising fesoterodine
Filed: 2007-06-07
Issued: 2010-10-05
Active (0.6 yrs remaining)
Expires: 2027-06-07
US8088398
Pharmaceutical compositions comprising fesoterodine
Filed: 2008-12-23
Issued: 2012-01-03
Active (1.3 yrs remaining)
Expires: 2028-03-17
US8501723
Pharmaceutical compositions comprising fesoterodine
Filed: 2010-01-22
Issued: 2013-08-06
Active (2.3 yrs remaining)
Expires: 2029-02-20
US7384980
Derivatives of 3,3-diphenylpropylamines
Filed: 2005-08-10
Issued: 2008-06-10
Expired (Term Ended)
Expires: 2019-10-14

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1149 days) / Cellect Scrutiny β€” Over 1149 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the Complaint to February 3, 2014 - filed by Apotex Inc.. (Horwitz, Richard) (Entered: 12/23...
Entry #7 • 2013-12-23 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 7 STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the Complaint to February 3, 2014 filed by Apotex Inc. Set/Reset Answer Dea...
Entry #β€” • 2013-12-23

Docket Entries

(30 total)
Pleading / Complaint

COMPLAINT filed against Apotex Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1423630.) - filed by UCB Pharma GmbH, Pfizer Inc.. (Attachments: # 1 Exhibit A-E part 1, # 2 Exhibit A-E part 2, # 3 Exhibit A-E part 3, # 4 Civil Cover Sheet)(cla, ) (Entered: 12/12/2013)

Entry #1 • 2013-12-11
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cla, ) (Entered: 12/12/2013)

Entry #2 • 2013-12-11
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/29/13. Date of Expiration of Patent: SEE FORM.Thirty Month Stay Deadline: 5/1/2016. (cla, ) (Entered: 12/12/2013)

Entry #3 • 2013-12-11
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,858,650 B1; 7,384,980 B2; 7,855,230 B2; 7,985,772 B2; 8,338,478,B2;. (cla, ) (Entered: 12/12/2013)

Entry #4 • 2013-12-11
1

Disclosure Statement pursuant to Rule 7.1 filed by Pfizer Inc., UCB Pharma GmbH identifying Corporate Parent UCB S.A., Corporate Parent UCB GmbH for UCB Pharma GmbH. (cla, ) (Entered: 12/12/2013)

Entry #5 • 2013-12-11
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc